查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103868

搔癢症治療市場：全球市場預測，2026-2032年

Pruritus Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，搔癢症治療市場規模將成長至 97.1 億美元，複合年成長率為 4.89%。

主要市場統計數據
基準年 2025 69.5億美元
預計年份：2026年 72.8億美元
預測年份 2032 97.1億美元
複合年成長率 (%) 4.89%

搔癢症治療市場執行摘要

搔癢症的治療已不再局限於短期止癢，而是轉向基於機制的療法，用於治療與異位性皮膚炎、慢性腎臟病淤積性肝病、銀屑病、蕁麻疹、神經病變瘙癢症和結節性瘙癢相關的慢性瘙癢。由於持續搔癢會損害睡眠、心理健康、降低治療順從性和生活品質，而抓癢會加重發炎、破壞皮膚屏障並增加感染風險，因此臨床上對治療的需求非常高。目前的治療策略包括局部應用皮質類固醇和Calcineurin抑制劑、潤膚劑、抗組織胺、照光治療、加巴噴丁類藥物、抗憂鬱症、鴉片通路調變器、膽汁酸通路促效劑、生物製藥和標靶小分子化合物。最有前景的治療方法是針對已證實有效的發炎和神經免疫通路，包括白細胞介素訊號通路、 Janus激酶訊號通路、神經激肽路徑、瞬時受體電位通道和鴉片受體失衡。近期針對結節性搔癢症、異位性皮膚炎和慢性腎臟病相關搔癢症的監管批准，正推動著治療模式從以症狀主導轉向以循證醫學為基礎、針對特定適應症的瘙癢管理。隨著保險公司、臨床醫生和患者越來越要求治療能夠顯著減輕瘙癢、持續控制病情並保證長期安全性，瘙癢治療的成功取決於差異化的作用機制、可靠的患者報告結局（PRO）、皮膚科醫生、腎臟科醫生和肝臟科醫生之間的協作，以及支持患者堅持長期治療的治療模式。

搔癢治療前景的變革性轉變。

隨著人們逐漸意識到搔癢並非僅僅是組織胺誘發的症狀，而是一個複雜的神經免疫訊號通路，搔癢的治療前景正在被重新定義。這種轉變尤其重要，因為許多慢性搔癢症對傳統抗組織胺的反應不佳，因此越來越需要能夠調節細胞激素、感覺神經元、鴉片受體和發炎級聯反應的標靶治療。在皮膚病學領域，生物製藥和口服標靶治療正在改變人們對中度至重度發炎性皮膚病（搔癢是其主要困擾）治療的預期。在腎臟病學領域，與慢性腎臟病相關的搔癢日益被認為是一種全身性疾病，與睡眠障礙、憂鬱症以及透析相關的生活品質下降有關，因此建議對搔癢進行定期篩檢並逐步加強治療。在肝病學領域，對膽汁淤積性搔癢的關注持續成長，促使人們對調節膽汁酸轉運並作用於中樞和周邊搔癢路徑的藥物產生了濃厚的興趣。此外，臨床研發正變得更加以患者為中心，諸如數字評分量表、搔癢嚴重程度評分、睡眠評估量表和皮膚病生活品質評估工具等檢驗的工具正被擴大用於證明藥物的療效。數位醫療、遠距皮膚病學、專科藥房模式和真實世界數據正透過改善追蹤、藥物依從性監測和安全性監測，進一步變革醫療服務模式。這些變革共同為搔癢治療藥物的研發和商業化創造了一個更精準、多學科協作且以結果為導向的環境。

人工智慧（AI）對搔癢症治療的累積影響

人工智慧 (AI) 對搔癢症的治療正產生日益顯著的影響，涵蓋藥物發現、臨床開發、診斷支持和治療後監測等各個方面。在藥物發現領域，AI 驅動的建模能夠識別參與搔癢訊號傳導的分子標靶，對化合物進行優先排序，並分析免疫介質、感覺神經元、微生物組因素和皮膚屏障功能障礙之間的複雜相互作用。在臨床研究中，機器學習有助於根據疾病亞型、生物標記物譜、合併症模式、治療史和患者報告的搔癢強度對患者進行分層。這至關重要，因為搔癢的原因多種多樣，包括皮膚病、腎臟疾病、肝臟疾病、神經系統疾病和全身性疾病。 AI 驅動的影像分析可以輔助評估可擦洗的皮損、苔蘚樣變、抓撓和發炎性皮膚變化，而自然語言處理可以從臨床記錄和患者的電子日記中提取患者報告的瘙癢負擔、睡眠障礙和不利事件。在臨床實務中，人工智慧若與適當的臨床檢驗和隱私保護措施結合，則可望提高病患的用藥依從性、預測症狀復發、檢測安全訊號並制定個人化的治療方案。然而，人工智慧的累積效應取決於高品質的資料集、透明的演算法、代表性的患者群體以及臨床醫生的監督。在搔癢症的治療中，人工智慧最適合作為“基礎層”，而不是取代專科醫生的決策，以加速循證醫學的生成、提高準確性並支持以患者為中心的治療結果。

關於搔癢症治療的關鍵區域性見解

由於亞太地區擁有龐大的患者群體，異位性皮膚炎和慢性腎臟病的診斷率不斷上升，皮膚科醫療服務的可及性日益擴大，以及中國、日本、韓國、印度和澳大利亞等市場對專科藥物的使用不斷增加，該地區正成為瘙癢症治療的關鍵區域。日本和韓國已建立起引進創新皮膚病療法的途徑，而中國和印度對價格合理的慢性病管理以及專科醫療服務的可及性需求也在不斷成長。歐洲擁有成熟的法律規範體系、完善的醫療技術評估流程以及涵蓋皮膚病和系統性疾病的指南導向型醫療保健體系，並專注於長期安全性、療效比較和公平的報銷。北美在引進先進瘙癢症療法方面繼續保持領先地位，這得益於其完善的皮膚病學、腎臟病學和過敏/主導網路、強大的臨床試驗基礎設施、患者權益倡導組織以及保險公司的嚴格審查——保險公司優先考慮的是症狀改善和生活品質的提高。在拉丁美洲，發炎性皮膚病、糖尿病相關腎臟病、感染疾病和寄生蟲性皮膚病以及肝病引起的搔癢症管理需求日益成長，其中巴西和墨西哥是主要的醫療資源取得和臨床實踐中心。在非洲，搔癢症的病因包括皮膚感染疾病、寄生蟲疾病、特異性疾病、腎臟病、愛滋病相關皮膚病以及專科醫生資源有限等，因此降低醫療成本、加強基層醫療培訓以及保障基本藥物的可及性對於改善治療效果至關重要。在中東，對皮膚科和腎臟科專科診療的需求不斷成長，尤其是在那些投資於三級醫療基礎設施和慢性病控制項目的國家。同時，糖尿病、腎臟病和發炎性皮膚病仍然是臨床診療的重點。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會的關鍵群體特定見解

在北約成員國，搔癢症治療的發展趨勢受到高標準的安全性證據、民用和國防相關醫療保健需求以及對慢性病管理、醫療服務提供者準備就緒和生活品質（QOL）的高度重視的影響，例如發炎性皮膚病和腎臟疾病。七國集團（G7）國家在製定臨床指南、引入生物製藥和標靶治療、標準化患者報告結局以及生成上市後真實世界數據（RWE）方面持續發揮影響力，尤其是在保險報銷機構要求證明瘙癢減輕和持續安全性的領域。金磚國家擁有大規模的患者群體、不斷擴大的藥品生產能力以及多樣化的醫療可及性挑戰，這為皮膚病學、腎臟病學和肝病學領域創新且注重成本效益的瘙癢症治療模式創造了機會。在歐盟，透過集中監管流程、藥物安全監測標準和國家醫保報銷評估，已建立起一套系統化的瘙癢治療評估體系，這些體係要求提供強力的證據，證明藥物能夠減輕瘙癢、安全有效並改善患者的生活品質。在東協地區，潮濕的氣候會加劇發炎性和感染性皮膚病，都市區醫療保健服務的改善，以及成員國之間皮膚科醫生數量的差異，都影響著對搔癢治療的需求。海灣合作理事會（GCC）地區的特點是：對專科醫療保健的大量投資、糖尿病和腎病的高發生率，以及以醫院為中心的醫療保健系統中先進療法的廣泛應用，使得瘙癢和與慢性腎臟病相關的炎症性皮膚病成為該地區重要的臨床治療重點。

主要國家治療搔癢藥物的使用趨勢

在中國，皮膚科和腎內科服務正在擴展，國內外治療方案的使用日益增多，臨床研究參與度也不斷提高。此外，由於慢性病管理計畫的擴展，人們對持續性搔癢的認知也不斷提高。美國是搔癢治療創新領域的領先中心，這得益於廣泛的臨床試驗活動、專科醫生處方、患者報告結局的應用，以及人們對異位性皮膚炎、結節性瘙癢症和慢性腎臟病相關瘙癢等慢性瘙癢問題的認知不斷提高。在日本，標靶治療正在臨床推廣，人們高度關注其安全性、與老齡化相關的合併症以及慢性腎臟病。在印度，人們對價格合理的搔癢治療方案有著非常高的需求，這些方案涵蓋特應性疾病、感染疾病、腎臟病和肝膽疾病，同時，能否獲得專科醫生的診療以及自付費用仍然是重要的考慮因素。德國、英國、法國、義大利和西班牙在皮膚病學、免疫學和衛生技術評估方面實力雄厚，治療方案的引入與臨床價值、安全性、療效比較以及生活品質的顯著改善密切相關。在澳大利亞，完善的專科醫療體系、公共保險報銷評估以及民眾對發炎性皮膚病的高度認知共同促成了這些問題的解決。韓國則以其先進的醫療基礎設施、對皮膚病學創新技術的快速應用以及強大的數位醫療能力而著稱，這些能力支持隨訪、藥物依從性和患者自述瘙癢監測。在加拿大，重點在於循證治療方案的採納和保險報銷審查，而治療的可及性則取決於省級決策和專科轉診途徑。在俄羅斯，發炎性、腎性、肝性和感染疾病搔癢的治療需求普遍存在，但區域間治療可近性的差異影響了治療的一致性。在巴西和墨西哥，對皮膚病和腎臟疾病的治療需求日益成長，但公共和私人醫療保健之間的差異影響了先進治療和輔助療法的可及性。

為搔癢治療領域的領導者提供的實用建議

搔癢治療領域的產業領導者應優先考慮明確的臨床差異化，將藥物作用機制與特定搔癢（例如發炎性搔癢、腎性搔癢、肝性搔癢、神經病變和混合性搔癢）的發病機制連結起來。研發項目應利用檢驗的搔癢特異性終點、睡眠和生活品質 (QOL) 指標以及能夠反映患者和處方醫生臨床獲益的有效應答者分析。各機構應加強生物標記策略、真實世界數據 (RWE) 計畫和長期安全性監測，尤其對於長期使用的療法以及合併免疫系統、腎臟、肝臟疾病或老年患者的療法。銷售團隊應進行教育舉措，幫助臨床醫生區分組織胺介導的搔癢和慢性非組織胺介導的搔癢，並在皮膚科、腎臟科、肝臟科和基層醫療推廣系統性的搔癢評估。准入策略必須滿足保險公司的期望，提供症狀緩解、疾病負擔減輕、用藥依從性提高和功能性結果等方面的證據，而不僅僅依賴傳統的基於病灶的指標。在新興市場和資源匱乏的環境中，領導者應制定循序漸進的准入方案、臨床醫生培訓和整合局部、全身和支持性療法的實用治療路徑。與數位醫療服務提供者合作可以改善患者日記、用藥依從性追蹤、症狀加重檢測和真實世界結果數據的收集，但這些工具必須經過臨床檢驗、符合隱私規定，並且足夠簡單易用，便於日常使用。

為獲得搔癢症實證治療方面的見解而調查方法

本執行摘要基於系統的二手研究途徑，重點關注檢驗的醫學、監管和科學資訊來源。證據來源包括同行評審的皮膚病學、腎臟病學、肝病學、免疫學和藥理學文獻、臨床實踐指南、法規核准文件、臨床試驗註冊資訊、藥物警戒參考資料、疾病負擔出版物以及公開的醫療保健政策資源。分析重點在於與搔癢管理相關的治療機制、適應症、患者報告結局、區域可及性和臨床啟動因素。資訊來源均經過評估，以確保其時效性、科學可靠性、臨床相關性以及獨立參考文獻之間的一致性。本研究尤其關注慢性搔癢，其檢驗策略取決於已驗證的搔癢嚴重程度評估、睡眠障礙、生活品質下降、安全性考量以及合併症負擔。此調查方法排除了無根據的假設、宣傳性聲明、市場規模估算、市場佔有率分析和預測。區域、群體和國家層面的洞察來自醫療保健基礎設施模式、法規環境、疾病管理重點和准入考慮因素，而不是基於推測性的商業性預測。

結論：以患者為中心的搔癢治療取得進展

搔癢症的治療正步入一個更專業化的時代，其特徵是神經免疫學、標靶治療、檢驗的患者報告結局指標以及多學科管理。最重要的策略轉變在於認知到慢性搔癢症不僅僅是一種次要症狀，而是一種具有臨床意義的疾病，會影響睡眠、心理健康、工作效率、治療依從性和整體生活品質。隨著發炎性皮膚病、慢性腎臟病相關搔癢症、膽汁淤積性搔癢症和神經病變搔癢症等方面的證據不斷積累，相關人員相關者正轉向能夠持續緩解症狀並保持長期安全性的療法。這些療法在地方和國家層面的推廣應用將取決於臨床證據、保險報銷標準、專家資源、治療費用以及將搔癢症評估納入常規診療實踐的能力。人工智慧、真實世界證據和數位化病人參與，如果經過嚴格檢驗並有效實施，可以加速療法的研發和個人化治療的實現。能夠平衡科學差異化與實際應用、醫療保健專業人員教育以及以患者為中心的治療效果的行業領導者，將最有能力推進對遭受持續性、改變生活的瘙癢症患者的護理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：搔癢症治療市場：依療法分類

  • 抗組織胺藥
  • 生物製劑
  • Calcineurin抑制劑
  • 皮質類固醇
  • 免疫抑制劑

第8章：搔癢症治療藥物市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第9章：搔癢症治療市場：依疾病適應症分類

  • 過敏性接觸性皮膚炎
  • 異位性皮膚炎
  • 皮膚T細胞淋巴瘤
  • 麻疹

第10章：搔癢症治療市場：依患者族群分類

  • 成年患者
  • 老年人
  • 兒童患者

第11章：搔癢症治療市場：依通路分類

  • 線上
  • 離線

第12章：搔癢症治療市場：依最終用戶分類

  • 診所
  • 皮膚病中心
  • 居家照護環境
  • 醫院

第13章：搔癢症治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：搔癢症治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章：搔癢症治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Avior Bio, Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cara Therapeutics, Inc.
  • Eli Lilly and Company
  • EPI Health, LLC
  • Escient Pharmaceuticals, Inc.
  • Evelo Biosciences, Inc.
  • Galderma SA
  • GSK plc
  • LEO Pharma A/S
  • Mallinckrodt plc
  • MC2 Therapeutics A/S
  • Mirum Pharmaceuticals, Inc.
  • NeRRe Therapeutics Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Trevi Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.
Product Code: MRR-8E22B61932B7

The Pruritus Therapeutics Market is projected to grow by USD 9.71 billion at a CAGR of 4.89% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.95 billion
Estimated Year [2026] USD 7.28 billion
Forecast Year [2032] USD 9.71 billion
CAGR (%) 4.89%

Pruritus Therapeutics Executive Summary

Pruritus therapeutics are moving beyond short-term itch suppression toward mechanism-based care for chronic pruritus associated with atopic dermatitis, chronic kidney disease-associated pruritus, cholestatic liver disease, psoriasis, urticaria, neuropathic disorders, and prurigo nodularis. The clinical need is substantial because persistent itch disrupts sleep, mental health, treatment adherence, and quality of life, while scratching can worsen inflammation, skin barrier damage, and infection risk. Current therapeutic strategies span topical corticosteroids and calcineurin inhibitors, emollients, antihistamines, phototherapy, gabapentinoids, antidepressants, opioid pathway modulators, bile acid pathway agents, biologics, and targeted small molecules. The strongest momentum is in therapies that address validated inflammatory and neuroimmune pathways, including interleukin signaling, Janus kinase signaling, neurokinin pathways, transient receptor potential channels, and opioid receptor imbalance. Regulatory approvals in recent years for prurigo nodularis, atopic dermatitis, and chronic kidney disease-associated pruritus have reinforced the shift from symptom-led treatment to indication-specific, evidence-based pruritus management. As payers, clinicians, and patients increasingly demand measurable itch reduction, durable disease control, and safety in long-term use, success in pruritus therapeutics depends on differentiated mechanisms, robust patient-reported outcomes, dermatology-nephrology-hepatology collaboration, and access models that support chronic therapy adherence.

Transformative Shifts in the Pruritus Therapeutics Landscape

The pruritus therapeutics landscape is being reshaped by a deeper understanding of itch as a complex neuroimmune signal rather than a simple histamine-driven symptom. This shift is particularly important because many chronic itch conditions respond poorly to conventional antihistamines, creating demand for targeted options that modulate cytokines, sensory neurons, opioid receptors, and inflammatory cascades. In dermatology, biologics and oral targeted therapies are changing treatment expectations for moderate-to-severe inflammatory skin diseases where itch is a dominant burden. In nephrology, chronic kidney disease-associated pruritus is gaining recognition as a systemic condition linked to sleep impairment, depression, and dialysis-related quality-of-life outcomes, encouraging routine itch screening and therapeutic escalation. In hepatology, cholestatic pruritus continues to drive interest in bile acid transport modulation and agents addressing central and peripheral itch pathways. Clinical development is also becoming more patient-centric, with validated tools such as numeric rating scales, itch severity scores, sleep measures, and dermatology quality-of-life instruments increasingly used to demonstrate meaningful benefit. Digital health, teledermatology, specialty pharmacy models, and real-world evidence are further transforming care delivery by improving follow-up, adherence monitoring, and safety surveillance. Together, these changes are creating a more precise, multidisciplinary, and outcomes-oriented environment for pruritus drug development and commercialization.

Cumulative Impact of Artificial Intelligence on Pruritus Care

Artificial intelligence is increasingly influencing pruritus therapeutics across discovery, clinical development, diagnosis support, and post-treatment monitoring. In drug discovery, AI-enabled modeling can help identify molecular targets involved in itch signaling, prioritize compounds, and analyze complex interactions among immune mediators, sensory neurons, microbiome factors, and skin barrier dysfunction. In clinical research, machine learning supports patient stratification by disease subtype, biomarker profile, comorbidity pattern, treatment history, and reported itch intensity, which is valuable because pruritus is highly heterogeneous across dermatologic, renal, hepatic, neurologic, and systemic causes. AI-assisted image analysis can support assessment of scratch lesions, lichenification, excoriations, and inflammatory skin changes, while natural language processing can extract patient-reported itch burden, sleep disruption, and adverse events from clinical notes and digital patient diaries. In real-world settings, AI may improve adherence interventions, flare prediction, safety signal detection, and personalized treatment sequencing when used with appropriate clinical validation and privacy safeguards. However, the cumulative impact of artificial intelligence depends on high-quality datasets, transparent algorithms, representative patient populations, and clinician oversight. For pruritus therapeutics, AI is best positioned as an enabling layer that accelerates evidence generation, improves precision, and supports patient-centered outcomes rather than replacing specialist decision-making.

Key Regional Insights in Pruritus Therapeutics

Asia-Pacific is becoming an important region for pruritus therapeutics due to its large patient base, rising diagnosis of atopic dermatitis and chronic kidney disease, expanding dermatology access, and growing use of specialty medicines in markets such as China, Japan, South Korea, India, and Australia. Japan and South Korea have strong adoption pathways for innovative dermatology therapies, while China and India are seeing increased demand for affordable chronic disease management and broader access to specialist care. Europe benefits from mature regulatory oversight, health technology assessment processes, and guideline-driven care across dermatology and systemic disease, with strong attention to long-term safety, comparative value, and equitable reimbursement. North America remains a leading environment for advanced pruritus treatment adoption, supported by established dermatology, nephrology, and allergy-immunology networks, strong clinical trial infrastructure, patient advocacy, and payer scrutiny that emphasizes documented symptom improvement and quality-of-life benefits. Latin America shows rising need for pruritus management in inflammatory skin disease, diabetes-related kidney disease, infectious and parasitic skin conditions, and hepatic disorders, with Brazil and Mexico serving as key access and clinical practice hubs. Africa presents a distinct landscape where pruritus is influenced by dermatologic infections, parasitic disease, atopic conditions, renal disease, HIV-associated skin manifestations, and limited specialist access, making affordability, primary-care training, and essential medicine availability central to therapeutic impact. The Middle East is witnessing increased demand for specialty dermatology and renal care, particularly in countries investing in tertiary healthcare infrastructure and chronic disease programs, while diabetes, kidney disease, and inflammatory skin disorders continue to shape clinical priorities.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

Within NATO countries, pruritus therapeutics are shaped by high standards for safety evidence, civilian and defense-linked healthcare needs, and strong emphasis on chronic disease management, workforce readiness, and quality-of-life outcomes in conditions such as inflammatory dermatoses and renal disease. G7 countries remain influential in clinical guideline development, biologic and targeted therapy uptake, patient-reported outcome standardization, and post-approval real-world evidence generation, particularly where reimbursement bodies require demonstrable itch reduction and durable safety. BRICS countries combine large patient populations, expanding pharmaceutical manufacturing capacity, and diverse access challenges, creating opportunities for both innovative and cost-conscious pruritus treatment models across dermatology, nephrology, and hepatology. The European Union provides a structured environment for pruritus drug evaluation through centralized regulatory pathways, pharmacovigilance standards, and national reimbursement assessments that require strong evidence on itch reduction, safety, and patient quality of life. Within ASEAN, pruritus therapeutics demand is shaped by humid climates that can aggravate inflammatory and infectious skin conditions, increasing urban healthcare access, and uneven availability of specialist dermatology across member states. The GCC is characterized by strong investment in specialty care, high burden of diabetes and kidney disease, and increasing use of advanced therapies in hospital-centered systems, making chronic kidney disease-associated pruritus and inflammatory dermatoses important clinical priorities.

Key Country Insights in Pruritus Therapeutics

China is expanding dermatology and nephrology capacity, increasing use of domestic and international therapies, and strengthening clinical research participation, while broader chronic disease management programs support higher recognition of persistent pruritus. The United States is a major center for pruritus therapeutics innovation, supported by extensive clinical trial activity, specialist prescribing, patient-reported outcome use, and growing recognition of chronic itch in atopic dermatitis, prurigo nodularis, and chronic kidney disease-associated pruritus. Japan has advanced clinical adoption of targeted therapies and high attention to safety, aging-related comorbidities, and chronic kidney disease. India presents a high-volume need for affordable pruritus care across atopic disease, infections, renal disease, and hepatobiliary conditions, while specialist access and out-of-pocket spending remain important considerations. Germany, the United Kingdom, France, Italy, and Spain maintain strong dermatology, immunology, and health technology assessment capabilities, with therapy adoption closely linked to clinical value, safety, comparative effectiveness, and measurable quality-of-life improvement. Australia combines strong specialist practice with public reimbursement evaluation and high awareness of inflammatory skin disease, while South Korea is characterized by advanced healthcare infrastructure, rapid adoption of dermatology innovation, and strong digital health capabilities that can support follow-up, adherence, and patient-reported itch monitoring. Canada emphasizes evidence-based adoption and reimbursement review, with access shaped by provincial decision-making and specialist referral pathways. Russia has a broad need for accessible pruritus treatment across inflammatory, renal, hepatic, and infectious causes, with regional access variation affecting treatment consistency. Brazil and Mexico show increasing demand for dermatology and renal symptom management, with public-private access differences influencing use of advanced therapies and supportive care.

Actionable Recommendations for Pruritus Therapeutics Leaders

Industry leaders in pruritus therapeutics should prioritize clear clinical differentiation by linking mechanisms of action to specific itch etiologies, such as inflammatory, renal, hepatic, neuropathic, and mixed-origin pruritus. Development programs should use validated itch-specific endpoints, sleep and quality-of-life measures, and responder analyses that reflect clinically meaningful benefit to patients and prescribers. Organizations should strengthen biomarker strategies, real-world evidence plans, and long-term safety monitoring, particularly for therapies used chronically or in patients with immune, renal, hepatic, or geriatric comorbidities. Commercial teams should build education initiatives that help clinicians distinguish histamine-mediated itch from chronic non-histaminergic pruritus and encourage systematic itch assessment in dermatology, nephrology, hepatology, and primary care. Access strategies should address payer expectations through evidence on symptom relief, reduction in disease burden, adherence improvement, and functional outcomes without relying only on traditional lesion-based measures. In emerging and resource-constrained settings, leaders should develop tiered access approaches, clinician training, and practical treatment pathways that integrate topical, systemic, and supportive care. Partnerships with digital health providers can improve patient diaries, adherence tracking, flare detection, and real-world outcome collection, but these tools must be clinically validated, privacy-compliant, and simple enough for routine use.

Research Methodology for Evidence-Based Pruritus Therapeutics Insights

This executive summary is built on a structured secondary research approach focused on verified medical, regulatory, and scientific sources. Evidence inputs include peer-reviewed dermatology, nephrology, hepatology, immunology, and pharmacology literature; clinical practice guidelines; regulatory approval documents; clinical trial registry information; pharmacovigilance references; disease burden publications; and publicly available healthcare policy resources. The analysis emphasizes therapeutic mechanisms, disease indications, patient-reported outcomes, regional access dynamics, and clinical adoption factors relevant to pruritus management. Sources were assessed for recency, scientific credibility, clinical relevance, and consistency across independent references. Particular attention was given to chronic pruritus conditions where treatment decisions are shaped by validated itch severity measures, sleep disruption, quality-of-life impairment, safety considerations, and comorbidity burden. The methodology avoids unsupported assumptions, promotional claims, market sizing, market share analysis, and forecasting. Regional, group, and country insights are synthesized from healthcare infrastructure patterns, regulatory environments, disease management priorities, and access considerations rather than from speculative commercial projections.

Conclusion: Advancing Patient-Centered Pruritus Therapeutics

Pruritus therapeutics are entering a more specialized era defined by neuroimmune science, targeted treatments, validated patient-reported outcomes, and multidisciplinary management. The most important strategic shift is the recognition that chronic itch is not a secondary complaint but a clinically meaningful condition that affects sleep, mental health, productivity, treatment adherence, and overall quality of life. As evidence grows across inflammatory skin disease, chronic kidney disease-associated pruritus, cholestatic pruritus, and neuropathic itch, stakeholders are moving toward therapies that deliver durable relief while maintaining acceptable safety for long-term use. Regional and country-level adoption will depend on clinical evidence, reimbursement standards, specialist access, affordability, and the ability to integrate itch assessment into routine care. Artificial intelligence, real-world evidence, and digital patient engagement can enhance development and treatment personalization when implemented with rigorous validation. Industry leaders that align scientific differentiation with practical access, clinician education, and patient-centered outcomes will be best positioned to advance care for people living with persistent and debilitating pruritus.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pruritus Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. Antihistamines
  • 7.3. Biologics
  • 7.4. Calcineurin inhibitors
  • 7.5. Corticosteroids
  • 7.6. Immunosuppressant

8. Pruritus Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Pruritus Therapeutics Market, by Disease Indication

  • 9.1. Introduction
  • 9.2. Allergic Contact Dermatitis
  • 9.3. Atopic Dermatitis
  • 9.4. Cutaneous T-cell
  • 9.5. Urticaria

10. Pruritus Therapeutics Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Adult Patients
  • 10.3. Geriatric Patients
  • 10.4. Pediatric Patients

11. Pruritus Therapeutics Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online
  • 11.3. Offline

12. Pruritus Therapeutics Market, by End-User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Dermatology Centers
  • 12.4. Homecare Settings
  • 12.5. Hospitals

13. Pruritus Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Pruritus Therapeutics Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Pruritus Therapeutics Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Asana BioSciences, LLC
  • 17.3. Astellas Pharma Inc.
  • 17.4. Avior Bio, Inc.
  • 17.5. Bausch Health Companies Inc.
  • 17.6. Bayer AG
  • 17.7. Cara Therapeutics, Inc.
  • 17.8. Eli Lilly and Company
  • 17.9. EPI Health, LLC
  • 17.10. Escient Pharmaceuticals, Inc.
  • 17.11. Evelo Biosciences, Inc.
  • 17.12. Galderma S.A.
  • 17.13. GSK plc
  • 17.14. LEO Pharma A/S
  • 17.15. Mallinckrodt plc
  • 17.16. MC2 Therapeutics A/S
  • 17.17. Mirum Pharmaceuticals, Inc.
  • 17.18. NeRRe Therapeutics Ltd.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Regeneron Pharmaceuticals, Inc.
  • 17.22. Sanofi
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Toray Industries, Inc.
  • 17.25. Trevi Therapeutics, Inc.
  • 17.26. Vanda Pharmaceuticals Inc.
  • 17.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRURITUS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PRURITUS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PRURITUS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PRURITUS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOSUPPRESSANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOSUPPRESSANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOSUPPRESSANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGIC CONTACT DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGIC CONTACT DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGIC CONTACT DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CUTANEOUS T-CELL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CUTANEOUS T-CELL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CUTANEOUS T-CELL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL URTICARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL URTICARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL URTICARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 121. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NATO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 178. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. INDIA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 185. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 206. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 220. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. ITALY PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 227. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 265. GLOBAL PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025